GSK advances global development of Ris-Rez outside China across multiple solid tumors

• GSK will advance risvutatug rezetecan outside Greater China across multiple solid-tumor programs, including lung cancer and prostate cancer.
• Development planning centers on the global phase III EMBOLD SCLC-301 study in relapsed extensive-stage small-cell lung cancer, with pivotal data expected next year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-26-006601), on July 10, 2026, and is solely responsible for the information contained therein.